Fabio Andre Amaral Lopes Simoes

Dr. Fabio Andre Amaral Lopes Simoes

Clinical and experimental medicine, Brighton and Sussex Medical School, Brighton, Brighton and Hove, UK
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2013 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
DDDanielle C. Diaper
Danielle C. Diaper
YAYoshitsugu Adachi
Yoshitsugu Adachi
LLLuke Lazarou
Luke Lazarou
MGMax Greenstein
Max Greenstein
FSFabio Andre Amaral Lopes Simoes
Fabio Andre Amaral Lopes Simoes
Frank HirthFrank Hirth
Frank Hirth
Amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) are neurodegenerative disorders that are characterized by cytoplasmic aggregates and nuclear clearance of TAR DNA-binding protein 43 (TDP-43). Studies in Drosophila, zebrafish and mouse demonstrate that the neuronal dysfunction of TDP-43 is causally related to disease formation. However, TDP-43 aggregates are also observed in glia and muscle cells, which are equally affected in ALS and FTLD; yet, it is unclear whether glia- or muscle-specific dysfunction of TDP-43 contributes to pathogenesis. Here, we show that similar to its human homologue, Drosophila TDP-43, Tar DNA-binding protein homologue (TBPH), is expressed in glia and muscle cells. Muscle-specific knockdown of TBPH causes age-related motor abnormalities, whereas muscle-specific gain of function leads to sarcoplasmic aggregates and nuclear TBPH depletion, which is accompanied by behavioural deficits and premature lethality. TBPH dysfunction in glia cells causes age-related motor deficits and premature lethality. In addition, both loss and gain of Drosophila TDP-43 alter mRNA expression levels of the glutamate transporters Excitatory amino acid transporter 1 (EAAT1) and EAAT2. Taken together, our results demonstrate that both loss and gain of TDP-43 function in muscle and glial cells can lead to cytological and behavioural phenotypes in Drosophila that also characterize ALS and FTLD and identify the glutamate transporters EAAT1/2 as potential direct targets of TDP-43 function. These findings suggest that together with neuronal pathology, glial- and muscle-specific TDP-43 dysfunction may directly contribute to the aetiology and progression of TDP-43-related ALS and FTLD.

Verified
Journal Article
Open access
PDF file
FSFabio Andre Amaral Lopes Simoes
Fabio Andre Amaral Lopes Simoes
GJGreig Joilin
Greig Joilin
OPOliver Peters
Oliver Peters
LSLuisa Sophie Schneider
Luisa Sophie Schneider
JPJosef Priller
Josef Priller
MHMajid Hafezparast
Majid Hafezparast
Objective markers for the neurodegenerative disorder progressive supranuclear palsy (PSP) are needed to provide a timely diagnosis with greater certainty. Non-coding RNA (ncRNA), including microRNA, piwi-interacting RNA, and transfer RNA, are good candidate markers in other neurodegenerative diseases, but have not been investigated in PSP. Therefore, as proof of principle, we sought to identify whether they were dysregulated in matched serum and cerebrospinal fluid (CSF) samples of patients with PSP. Small RNA-seq was undertaken on serum and CSF samples from healthy controls (n = 20) and patients with PSP (n = 31) in two cohorts, with reverse transcription-quantitative PCR (RT-qPCR) to confirm their dysregulation. Using RT-qPCR, we found in serum significant down-regulation in hsa-miR-92a-3p, hsa-miR-626, hsa-piR-31068, and tRNA-ValCAC. In CSF, both hsa-let-7a-5p and hsa-piR-31068 showed significant up-regulation, consistent with their changes observed in the RNA-seq results. Interestingly, we saw no correlation in the expression of hsa-piR-31068 within our matched serum and CSF samples, suggesting there is no common dysregulatory mechanism between the two biofluids. While these changes were in a small cohort of samples, we have provided novel evidence that ncRNA in biofluids could be possible diagnostic biomarkers for PSP and further work will help to expand this potential.

1 May 2024 in Disease Models & Mechanisms
Verified
Journal Article
Open access
PDF file
ECEleni Christoforidou
Eleni Christoforidou
LMLibby Moody
Libby Moody
GJGreig Joilin
Greig Joilin
FSFabio Andre Amaral Lopes Simoes
Fabio Andre Amaral Lopes Simoes
DGDavid Gordon
David Gordon
MHMajid Hafezparast
Majid Hafezparast
Evidence suggests the presence of microglial activation and microRNA (miRNA) dysregulation in amyotrophic lateral sclerosis (ALS), the most common form of adult motor neuron disease. However, few studies have investigated whether the miRNA dysregulation originates from microglia. Furthermore, TDP-43 (encoded by TARDBP), involved in miRNA biogenesis, aggregates in tissues of ∼98% of ALS cases. Thus, this study aimed to determine whether expression of the ALS-linked TDP-43M337V mutation in a transgenic mouse model dysregulates microglia-derived miRNAs. RNA sequencing identified several dysregulated miRNAs released by transgenic microglia and a differential miRNA release by lipopolysaccharide-stimulated microglia, which was more pronounced in cells from female mice. We validated the downregulation of three candidate miRNAs, namely, miR-16-5p, miR-99a-5p and miR-191-5p, by reverse transcription quantitative polymerase chain reaction (RT-qPCR) and identified their predicted targets, which primarily include genes involved in neuronal development and function. These results suggest that altered TDP-43 function leads to changes in the miRNA population released by microglia, which may in turn be a source of the miRNA dysregulation observed in the disease. This has important implications for the role of neuroinflammation in ALS pathology and could provide potential therapeutic targets.

8 September 2025 in Osteoarthritis and Cartilage
Verified
Journal Article
Open access
FSFabio Andre Amaral Lopes Simoes
Fabio Andre Amaral Lopes Simoes
GSGreg Scutt
Greg Scutt
MMManuela Mengozzi
Manuela Mengozzi
SMSimon Mitchell
Simon Mitchell
JKJacob Keen
Jacob Keen
LMLisa M. Mullen
Lisa M. Mullen
Therapeutic potential of selective aggrecanase inhibition in osteoarthritis (OA) was previously demonstrated using a variant of endogenous tissue inhibitor of metalloproteinase-3 (TIMP-3); however, this relied on transgenic mice overexpressing TIMP-3. Here, we develop a translational approach for harnessing the aggrecanase-selective inhibitory activity of TIMP-3 using the latency associated peptide (LAP) technology. We successfully produced and purified recombinant LAP-TIMP-3 fusion proteins and determined the pharmacokinetics of these proteins in vivo following systemic injection. Surgical and non-surgical mouse models of OA were used to establish the therapeutic potential of these proteins in reducing aggrecanase activity in mouse joints affected by OA. The presence of the LAP conferred favourable TIMP-3 pharmacokinetics, with effective delivery of LAP-TIMP-3 to knee joints after systemic injection. We find that LAP-TIMP-3 also effectively reduced aggrecanase activity in OA-affected joints, both in spontaneously-occurring OA and in the destabilisation of the medical meniscus (DMM) model of OA. We also found that reductions in aggrecanase activity in articular cartilage correlated with improved disease scores, but only in earlier stages of disease. This study describes the potential of LAP-TIMP-3 as a therapeutic agent in OA, showing delivery to the cartilage of joints affected by OA after systemic administration and lower levels of the neoepitope of aggrecan in articular cartilage in mild disease (mean difference versus vehicle control for LAP-TIMP-3: 535 [95% CI: 336, 733] and for LAP-mutTIMP-3: 522 [95% CI: 323, 720] arbitrary units). These first in vivo data will inform further explorations into dose optimization and timing.

27 July 2023 in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Verified
Journal Article
Open access
ECEleni Christoforidou
Eleni Christoforidou
FSFabio Andre Amaral Lopes Simoes
Fabio Andre Amaral Lopes Simoes
DGDavid Gordon
David Gordon
KTKevin Talbot
Kevin Talbot
MHMajid Hafezparast
Majid Hafezparast
ObjectiveMost TDP-43 mouse models of ALS do not display cytoplasmic mislocalisation or protein aggregation of TDP-43 in spinal motor neurons in vivo. Thus, we investigated whether a combination of defective dynein with a TDP-43 mutation could trigger TDP-43 pathology.MethodsUsing immunohistochemical methods we examined the intracellular motor neuron pathology of the offspring of TDP-43(WT) and TDP-43(M337V) transgenic mice bred to heterozygous Loa mice, which carry an autosomal dominant mutation in dynein cytoplasmic 1 heavy chain 1 (Dync1h1).ResultsThese mice did not exhibit TDP-43 mislocalisation in spinal motor neurons, but the expression of mutant dynein in combination with wildtype human TDP-43 resulted in p62 upregulation and TDP-43 aggregation, thus partially recapitulating the human disease.ConclusionsThese findings provide new insights into the possible relationship between dynein and TDP-43 and could prove useful in future studies looking to elucidate the mechanism behind the TDP-43 pathology observed in ALS.

3 January 2025 in Cancers
Verified
Journal Article
Open access
PDF file
ELEleni E. Ladikou
Eleni E. Ladikou
KSKim Sharp
Kim Sharp
FSFabio Andre Amaral Lopes Simoes
Fabio Andre Amaral Lopes Simoes
JJJohn R. Jones
John R. Jones
TBThomas Burley
Thomas Burley
APAndrea Gail Sherman Pepper
Andrea Gail Sherman Pepper
Background/Objectives: Acute myeloid leukemia (AML) is an aggressive neoplasm. Although most patients respond to induction therapy, they commonly relapse due to recurrent disease in the bone marrow microenvironment (BMME). So, the disruption of the BMME, releasing tumor cells into the peripheral circulation, has therapeutic potential. Methods: Using both primary donor AML cells and cell lines, we developed an in vitro co-culture model of the AML BMME. We used this model to identify the most effective agent(s) to block AML cell adherence and reverse adhesion-mediated treatment resistance. Results: We identified that anti-CD44 treatment significantly increased the efficacy of cytarabine. However, some AML cells remained adhered, and transcriptional analysis identified focal adhesion kinase (FAK) signaling as a contributing factor; the adhered cells showed elevated FAK phosphorylation that was reduced by the FAK inhibitor, defactinib. Importantly, we demonstrated that anti-CD44 and defactinib were highly synergistic at diminishing the adhesion of the most primitive CD34high AML cells in primary autologous co-cultures. Conclusions: Taken together, we identified anti-CD44 and defactinib as a promising therapeutic combination to release AML cells from the chemoprotective AML BMME. As anti-CD44 is already available as a recombinant humanized monoclonal antibody, the combination of this agent with defactinib could be rapidly tested in AML clinical trials.